167 related articles for article (PubMed ID: 11303040)
1. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats.
Baumann MH; Rothman RB; Pablo JP; Mash DC
J Pharmacol Exp Ther; 2001 May; 297(2):531-9. PubMed ID: 11303040
[TBL] [Abstract][Full Text] [Related]
2. Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine.
Baumann MH; Pablo JP; Ali SF; Rothman RB; Mash DC
Ann N Y Acad Sci; 2000 Sep; 914():354-68. PubMed ID: 11085335
[TBL] [Abstract][Full Text] [Related]
3. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin.
Mash DC; Staley JK; Baumann MH; Rothman RB; Hearn WL
Life Sci; 1995; 57(3):PL45-50. PubMed ID: 7596224
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of antiaddictive actions of ibogaine.
Glick SD; Maisonneuve IS
Ann N Y Acad Sci; 1998 May; 844():214-26. PubMed ID: 9668680
[TBL] [Abstract][Full Text] [Related]
5. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration.
Rothman RB; Blough BE; Woolverton WL; Anderson KG; Negus SS; Mello NK; Roth BL; Baumann MH
J Pharmacol Exp Ther; 2005 Jun; 313(3):1361-9. PubMed ID: 15761112
[TBL] [Abstract][Full Text] [Related]
6. Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats.
Wei D; Maisonneuve IM; Kuehne ME; Glick SD
Brain Res; 1998 Aug; 800(2):260-8. PubMed ID: 9685673
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters.
Yu H; Kim IJ; Folk JE; Tian X; Rothman RB; Baumann MH; Dersch CM; Flippen-Anderson JL; Parrish D; Jacobson AE; Rice KC
J Med Chem; 2004 May; 47(10):2624-34. PubMed ID: 15115403
[TBL] [Abstract][Full Text] [Related]
8. Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
Efange SM; Mash DC; Khare AB; Ouyang Q
J Med Chem; 1998 Nov; 41(23):4486-91. PubMed ID: 9804688
[TBL] [Abstract][Full Text] [Related]
9. Neurochemical and neuroendocrine effects of ibogaine in rats: comparison to MK-801.
Baumann MH; Rothman RB; Ali SF
Ann N Y Acad Sci; 1998 May; 844():252-64. PubMed ID: 9668683
[TBL] [Abstract][Full Text] [Related]
10. Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain.
Zubaran C; Shoaib M; Stolerman IP; Pablo J; Mash DC
Neuropsychopharmacology; 1999 Jul; 21(1):119-26. PubMed ID: 10379526
[TBL] [Abstract][Full Text] [Related]
11. How toxic is ibogaine?
Litjens RP; Brunt TM
Clin Toxicol (Phila); 2016; 54(4):297-302. PubMed ID: 26807959
[TBL] [Abstract][Full Text] [Related]
12. Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study.
Gerasimov MR; Franceschi M; Volkow ND; Gifford A; Gatley SJ; Marsteller D; Molina PE; Dewey SL
J Pharmacol Exp Ther; 2000 Oct; 295(1):51-7. PubMed ID: 10991960
[TBL] [Abstract][Full Text] [Related]
13. Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine.
Baumann MH; Pablo J; Ali SF; Rothman RB; Mash DC
Alkaloids Chem Biol; 2001; 56():79-113. PubMed ID: 11705118
[No Abstract] [Full Text] [Related]
14. Ibogaine-like effects of noribogaine in rats.
Glick SD; Pearl SM; Cai J; Maisonneuve IM
Brain Res; 1996 Mar; 713(1-2):294-7. PubMed ID: 8725004
[TBL] [Abstract][Full Text] [Related]
15. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.
Wang X; Baumann MH; Xu H; Rothman RB
Synapse; 2004 Sep; 53(4):240-8. PubMed ID: 15266556
[TBL] [Abstract][Full Text] [Related]
16. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression.
Mathews TA; Fedele DE; Coppelli FM; Avila AM; Murphy DL; Andrews AM
J Neurosci Methods; 2004 Dec; 140(1-2):169-81. PubMed ID: 15589347
[TBL] [Abstract][Full Text] [Related]
17. Effects of ibogaine and noribogaine on phosphoinositide hydrolysis.
Rabin RA; Winter JC
Brain Res; 1996 Aug; 731(1-2):226-9. PubMed ID: 8883876
[TBL] [Abstract][Full Text] [Related]
18. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
[TBL] [Abstract][Full Text] [Related]
19. Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root.
Kontrimaviciūte V; Breton H; Mathieu O; Mathieu-Daudé JC; Bressolle FM
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Nov; 843(2):131-41. PubMed ID: 16798116
[TBL] [Abstract][Full Text] [Related]
20. Ibogaine and noribogaine potentiate the inhibition of adenylyl cyclase activity by opioid and 5-HT receptors.
Rabin RA; Winter JC
Eur J Pharmacol; 1996 Dec; 316(2-3):343-8. PubMed ID: 8982706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
